- Apr 30 Mon 2012 05:45
- Apr 28 Sat 2012 05:41
- Apr 27 Fri 2012 05:34
Rasagiline is a second-generation irreversible monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease (PD) and the product of a joint development programme between the Danish pharmaceutical company Lundbeck and Teva Pharmaceutical of Israel.
Following successful completion of phase III trials in patients with early and advanced PD, rasagiline was filed for regulatory approval in both the US and Europe in 2003.
- Apr 26 Thu 2012 04:28
Banzel (Rufinamide) was developed in 2004 by Novartis Pharma. It is being manufactured by Eisai in Europe. It is indicated for the treatment of epileptic seizures which are associated with Lennox-Gastaut syndrome (LGS) （L~G症候群，雷葛氏症候群） in children and adults.
- Apr 24 Tue 2012 05:33
Trobalt (ezogabine / retigabine) is indicated for the treatment of partial-onset epileptic seizures in patients aged more than 18 years old. It is being developed and manufactured jointly by Canada-based Valeant Pharmaceuticals and GlaxoSmithKline.
- Apr 23 Mon 2012 05:31
- Apr 22 Sun 2012 05:30
Platelets play a central role in atherothrombosis and are an important target for pharmacotherapy. In patients with acute coronary syndromes, the use of potent platelet inhibitors has been shown to reduce the rate of thrombotic events at the cost of increased bleeding.1-3 In contrast, among patients with stable atherosclerosis, a reduced rate of thrombotic events with antiplatelet therapy in addition to aspirin therapy has not been established.4
- Apr 21 Sat 2012 09:32
Physicians must not prescribe antihypertensive drugs containing aliskiren (Tekturna, Novartis Pharmaceuticals) in combination with angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) for patients with diabetes, the US Food and Drug Administration (FDA) announced today.
- Apr 20 Fri 2012 05:18
- Apr 19 Thu 2012 08:46
Daptomycin (Cubicin, Novartis) achieves clinical cure rates of 72% in sepsis caused byStaphylococcus aureus and of 85% in sepsis caused byStaphylococcus epidermidis. High-dose daptomycin is also safe and tolerable, according to posters presented here at the 22nd European Congress of Clinical Microbiology and Infectious Diseases.
- Apr 16 Mon 2012 05:19
- Apr 14 Sat 2012 05:21